Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$73.10 USD
+1.83 (2.57%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $73.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Cash flow Statements
Fiscal Year End for Ligand Pharmaceuticals Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 52.15 | -33.36 | 57.14 | -2.99 | 629.30 |
Depreciation/Amortization & Depletion | 35.49 | 52.12 | 67.75 | 52.52 | 63.45 |
Net Change from Assets/Liabilities | -34.40 | 65.68 | -48.08 | -6.72 | -6.64 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -3.66 | 53.41 | 1.99 | 11.77 | -715.44 |
Net Cash From Operating Activities | 49.58 | 137.85 | 78.80 | 54.59 | -29.34 |
Property & Equipment | -3.52 | -17.92 | -8.76 | -4.46 | -2.55 |
Acquisition/ Disposition of Subsidiaries | -10.41 | 0.00 | 0.00 | -382.82 | 800.96 |
Investments | 52.15 | 182.42 | 40.01 | 615.67 | -326.82 |
Other Investing Activities | -49.91 | -0.87 | -0.73 | 3.26 | -4.67 |
Net Cash from Investing Activities | -11.68 | 163.62 | 30.52 | 231.65 | 466.92 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 22.45 | 3.23 | 15.32 | -74.98 | -450.43 |
Issuance (Repayment) of Debt | -76.85 | -260.75 | -136.82 | -222.21 | -27.32 |
Increase (Decrease) Short-Term Debt | -0.05 | -0.05 | -9.19 | -9.55 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -5.50 | -18.42 | -7.07 | -3.81 | -7.42 |
Net Cash from Financing Activities | -59.95 | -275.99 | -137.76 | -310.55 | -485.17 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
Net Change In Cash & Equivalents | -22.05 | 25.48 | -28.44 | -24.31 | -47.51 |
Cash at Beginning of Period | 45.01 | 19.52 | 47.96 | 72.27 | 119.78 |
Cash at End of Period | 22.95 | 45.01 | 19.52 | 47.96 | 72.27 |
Diluted Net EPS | 2.94 | -1.98 | 3.31 | -0.18 | 31.85 |
Fiscal Year End for Ligand Pharmaceuticals Incorporated falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 52.15 | 33.97 | 44.24 | 41.95 | -33.36 |
Depreciation/Amortization & Depletion | 35.49 | 25.94 | 17.68 | 8.93 | 52.12 |
Net Change from Assets/Liabilities | -34.40 | -18.41 | 2.42 | 7.90 | 65.68 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -3.66 | 0.01 | -30.47 | -24.83 | 53.41 |
Net Cash From Operating Activities | 49.58 | 41.51 | 33.87 | 33.95 | 137.85 |
Property & Equipment | -3.52 | -3.10 | -2.62 | -2.41 | -17.92 |
Acquisition/ Disposition of Subsidiaries | -10.41 | -10.41 | 0.00 | 0.00 | 0.00 |
Investments | 52.15 | 11.76 | 20.51 | 12.83 | 182.42 |
Other Investing Activities | -49.91 | 0.35 | 0.21 | 0.13 | -0.87 |
Net Cash from Investing Activities | -11.68 | -1.40 | 18.11 | 10.55 | 163.62 |
Uses of Funds
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 22.45 | -60.93 | 12.54 | 3.39 | 3.23 |
Issuance (Repayment) of Debt | -76.85 | 0.00 | -76.85 | 0.00 | -260.75 |
Increase (Decrease) Short-Term Debt | -0.05 | 0.00 | 0.00 | -0.01 | -0.05 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -5.50 | -4.33 | -4.21 | -4.16 | -18.42 |
Net Cash from Financing Activities | -59.95 | -65.26 | -68.53 | -0.78 | -275.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -22.05 | -25.15 | -16.56 | 43.72 | 25.48 |
Cash at Beginning of Period | 45.01 | 45.01 | 45.01 | 45.01 | 19.52 |
Cash at End of Period | 22.95 | 19.86 | 28.45 | 88.73 | 45.01 |
Diluted Net EPS | 1.07 | -0.59 | 0.13 | 2.33 | -1.04 |